Xechem(548177): von Alchemistenbude zum Pharmakonzern - 500 Beiträge pro Seite

[physik]

Xechem International Announces Change in Its CEO; Offers Update on Nigerian Operations
Thursday July 12, 9:15 am ET

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) Xechem International announced today Dr. Robert Swift, a member of Xechem's Board of directors, has been appointed by the board of directors to take on the role of Chairman and CEO/President on an interim basis, replacing Dr. Ramesh Pandey, who will continue to serve on the Company's board of directors. Though no longer charged with the day-to-day operations of the Company, Dr. Pandey is expected to continue to play an advisory role with the Company and discussions are ongoing to formalize a mutually acceptable arrangement with Dr. Pandey and to resolve various financial and other issues related to his departure as Chairman and CEO.

ADVERTISEMENT
Dr. Swift was asked by the Board of Directors, to provide the Company with the experience, expertise and foresight to take the Company to the next level of success. Dr. Swift has a Ph.D. in Biochemistry from Michigan State University and an MBA in Finance from Indiana University. He has served as a senior scientist for a major pharmaceutical company, a biotech analyst and most recently as a co-portfolio manager of several large healthcare sector hedge funds. His broad experience in both the scientific and business sector of activities very closely related to Xechem International's interests makes him a uniquely qualified individual to take the helm of the Xechem Companies.

According to Dr. Swift, Xechem's new Interim CEO, "We are grateful to Dr. Pandey for his efforts in bringing NICOSAN(TM) to market in Nigeria. We look forward to the prospect of having continued access to his knowledge and experience as we move forward toward full scale commercial production of NICOSAN(TM)"

Xechem also announced a cost-cutting plan that will increase the focus on its Nigerian operations. That plan is expected to include the closure of the company's New Jersey headquarters with the office operations moving to smaller and less expensive facilities. According to Dr Swift, "There is not enough activity to justify the continued annual expense in excess of $250,000 to hold onto our New Jersey facilities. We can out source the clinical activities related to the development of 5-HMF, the Company's sickle cell compound licensed from VCU, and NICOSAN(TM). Research on these and other potential drugs can be accomplished collaboratively with world class academic institutions like VCU and Rutgers At this stage in the Company's development, the Board feels that all available resources must be focused on production of NICOSAN(TM) at our Nigerian operation and the filing of an IND for 5-HMF. After I spend time at the Nigerian facility, I will be better able to assess the requirements to reach full-scale production, as well as the timeline. We plan to have a shareholder meeting towards the end of the year to inform all shareholders of the progress we have made and what to expect in the future for Xechem."

About Xechem

Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (natural herbal drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).

About NICOSAN(TM)

NICOSAN(TM) is an anti-sickling drug originally developed as NIPRISAN by the Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM) no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced. Through quality control/quality assurance (QC/QA) Xechem has standardized and verified the antisickling activity of the product, which is now called as NICOSAN(TM).

After the approval by the regulatory agency of Nigeria, National Agency for Food and Drug Administration and Control (NAFDAC), NICOSAN(TM) is being marketed in Nigeria since July 6th, 2006 on a limited basis. NICOSAN(TM) has Orphan Drug Designation in the US and EU countries.

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties. Such risks include the risk that: (i) Xechem Nigeria will be unable to consummate the closing of its currently proposed bank financings; (ii) there could be delays and/or cost overruns in connection with the build out of Xechem Nigeria's pilot plant facility to a full scale commercial production facility; (iii) the Company and/or Xechem Nigeria could suffer significant dilution from the raising of additional capital until such point in time as they achieve cash flow break even status; (iv) doing business in Nigeria is subject to all of the risks of operation in a foreign country and associated political and regulatory risky and (v) operations of the Company could be disrupted due to the chronic limited availability of funds to meet ongoing obligations.


Contact:

Xechem International, Inc.
Stephen Burg, Director
707-425-8855

[lernen]

du bist der beste

[physik]

im investors-hub sieht man die Sache sehr euphorisch:
"
Posted by: bigdaddyc25
In reply to: None Date:7/13/2007 6:39:15 PM
Post #of 139437

TO ALL REAL XKEM LONGS

I have had several conversations with key people at the company this afternoon. I can share the following;

1) Swift is the man calling all the shots now - this guy knows hit shit, and has dived into the business.

2) Biggs has moved to Nigeria and is now dedicated his life to NICOSAN and Xechem. He is overseeing the operations in Nigeria.

3) Burg and Swift are heading to Nigeria the week after next. There goal is to see first hand the situation in Nigeria and report back to us. Swift is a NO BS guy. We will not see any fluff at all with him at the top. He will report what he is comfortable with. Right now, there are issues with verifying some of the counts for patients and production. They do not want to put out a number that is not correct, and they do not want to put out a statement saying we are way up, but we do not know the exact amount.

4) Operation in Nigeria has really taken off. Construction is moving very well, and production is increasing very rapidly.

5) They are looking for a new space in New Jersey. The old office was too big. Too many empty labs and such. Burg just got back from New Jersey where he was looking for a new space.

6) The atmosphere amongst the senior management team has been described as "the best in the history of the company". The commitments shown by these guys are unreal....especially Biggs moving to Nigeria.

7) The comment about the shareholder meeting was inserted in the PR to let us know that it will be in December instead of October this year. They simply cannot pull it off in October. Way too much going on, and they have not prepped for it yet. It tales several months to get a AGM scheduled. Updates will not wait until the meeting. We will get them as soon as Swift reviews the operation in Nigeria himself, and is comfortable enough to report the data.

8) Swift is a scientist and a business man. When he came on board, he realized that Pandey was in way over his head (not just from a business perspective, but form a science perspective as well). This was the reason for the change. All the BS about Pandey pissing of Nigerians was hog wash.

9) The company is beginning to behave like a real company...and my favorite quote of all....."we are coming, and we are going to hit the market like a freight train"...

Guys, the only thing I can tell you all, is that you have no idea what you are a part of here. The leadership here now, is second to none, and the product has always been a good one. This company is on its way to building a billion dollar drug, and we have a cap under $30M. My only advice is BUY, BUY, BUY. Think about it later. If there are chances next week, top up your positions. I would not want to be out when these guys get back from Nigeria. I have never been more comfortable with this investment....NEVER.

Do not lose sight of what is happening here. This is not an OTC play any longer. Trust these new leaders, and the potential upside is enormous.

Have a great weekend all.
"

[falconara]

Antwort auf Beitrag Nr.: 30.682.357 von physik am 14.07.07 11:52:12

Posted by: bigdaddyc25
In reply to: None ??Date:7/13??/2007 6:39:15 PM
Post #of 139437

[physik]

Antwort auf Beitrag Nr.: 31.572.405 von falconara am 14.09.07 13:40:17

was meinst Du? Ist doch amerikanische Schreibweise für 13.7.

Der Threadtitel könnte auch geändert werden zu:
von Alchemistenbude zu Pharmakonzern und zurück

Montag Abend wissen wir mehr.


(bigdaddys Post zeigt doch manchem hier, wie exakt er Einblick hatte. Alle Punkte sind eingetroffen - nur die emotionale Bewertung einiger Elemente ist natürlich persönlich gefärbt)

[physik]

http://wkrg.com/medical/article/the_latest_in_sickle_cell_tr…

The Latest in Sickle Cell Treatment
by Holly Ames/Medstar
Updated: September 18 2007
Sickle Cell Disease affects millions of people and September is Sickle Cell Awareness Month. Researchers know what causes it and how it affects the body, but there's no cure. The News Five Medical Team has a look at what could be the next big thing.

Researcher Donald Abraham is excited about a potential new treatment for sickle cell disease. "It's the best thing I have seen in my what, 37 years in this field. It's by far the best. It has the best chance."

Dr. Abraham is referring to a treatment that could change sickle-shaped blood cells back to normal. "Anti-sickling will move it back to the donut shape."

Healthy red blood cells are round and flexible and easily squeezed through blood vessels. In sickle cell disease, the cells are stiff and crescent-shaped. They get stuck and block the flow of oxygen-rich blood to the limbs and organs.

48 year old Lucy Brown was born with Sickle Cell Disease. "Your joints ache. Your stomach aches. Your back aches. You can ache all over with it."

Brown takes medication to control painful episodes. "if there was something that could stop them completely, that would be a blessing. Yes, it would."

Dr. Abraham's anti-sickling molecule may be the answer to her prayers. "this molecule, 5-HMF, really is a breakdown product in many foods and in plants. So it's really common in nature."

Researchers at Virginia Commonwealth University say 5 HMF works by attaching itself to red blood cells, increasing their supply of oxygen. Dr. Abraham adds, "What you want to do to treat sickle cell is you want to oxygenate this because when it's in the oxygenated red form, it won't sickle."

A drug containing the molecule is in the works. Until then, Lucy Brown remains on pins and needles coping with the pain.

The National Heart, Lung and Blood institute is funding studies on 5 HMF. It may take years before it's available to patients. Xechem International has already signed on to market the drug. '

9th Annual Sickle Cell Center Blood Drive

Blood transfusions are a vital part of treating people diagnosed with sickle cell disease. In honor of National Sickle Cell Awareness Month, several groups are joining hands to sponsor the 9th Annual Sickle Cell Center Blood Drive. The drive will be held Saturday, September 22nd at Franklin Primary Health Center at 1303 MLK Drive from 10 in the morning to 2 in the afternoon.

There will be some great door prizes and a drawing for two Delta Airlines roundtrip tickets. This year's drive is sponsored by the American Red Cross, the Alpha Phi Alpha Fraternity, the USA Comprehensive Sickle Cell Center, Sickle Cell Disease Association of America-Mobile Chapter and Franklin Primary Health.

[physik]

zu 5-HMF
http://www.thefreelibrary.com/Xechem+Announces+%22Notice+of+…

[physik]

Der Anfang vom Ende der Durststrecke?

[physik]

Antwort auf Beitrag Nr.: 32.572.887 von physik am 26.11.07 18:29:28

sieht doch gut aus. Anziehende Volumina, stark anziehender Kurs...

[physik]

Antwort auf Beitrag Nr.: 32.578.729 von physik am 27.11.07 10:13:14

hübsch

[physik]

der Überblick seit Xechem Pink wurde:

[physik]

Antwort auf Beitrag Nr.: 32.584.435 von physik am 27.11.07 17:29:14

http://allafrica.com/stories/200712120522.html



Nigeria: Xechem Invests $15 Million On Sickle Cell Drug

Vanguard (Lagos)

12 December 2007
Posted to the web 12 December 2007

Emma Ujah


Xechem Pharmaceutical Nigeria Limited disclosed at the weekend that it has invested over $15 million in the production of NICOSAN the world's most effective drug, yet, for the management of Sickle Cell Disease (SCD).Briefing the press in Abuja , the Managing Director (MD) of the company, Mr. Iretiolu Oniyide said the efforts of the company's board, management and staff had brought an unprecedented relief to SCD patients who could now live normal lives, without the usual crisis, once placed on the drug which is produced in Abuja .

"There has not been any drug for SCD that could bring relief and make patients live normal lives until the NICOSAN came on the stage. Now we have testimonies of users of the drug across the country who now live normal lives.

"We now have SCD patients who can go about their economic activities without crisis, children with sickle cell can now live normal lives, go to school, without being kept out of school by crisis. We are overwhelmed by the volume of testimonies of users and we are proud to be part of this great discovery', the MD said.

Mr. Oniyide, revealed that there were enemies of Nigeria who were hell bent on rubbishing the success story of NICOSAN but that he team at Xechem was prepared not only to refuse to be distracted but move ahead to expand its production lines and by so doing, make NICOSAN available to more SCD patients within and outside the country.

He debunked a recent reports alleging the inefficacy of NICOSAN in the management of SCD and that the drug has not met the required quality control standards, stressing that NAFDAC, the apex regulatory authority has endorsed the drug as having passed through necessary quality control standards and processes.